EYENOVIA INC. - COMMON STOCK

Eyenovia Reports First Quarter 2022 Financial Results

12 مايو 2022 15:05:01 بحسب Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2022 Results on Thursday, May 12

05 مايو 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

20 أبريل 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

19 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

28 مارس 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28

21 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions

15 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.

04 مارس 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

08 فبراير 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Eyenovia Announces Changes to Board of Directors

07 فبراير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2021 Financial Results

10 نوفمبر 2021 15:05:02 بحسب Nasdaq GlobeNewswire

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

08 نوفمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

05 نوفمبر 2021 14:25:02 بحسب Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

04 نوفمبر 2021 15:05:03 بحسب Nasdaq GlobeNewswire

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

04 نوفمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

25 أكتوبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2021 Financial Results

11 أغسطس 2021 15:05:00 بحسب Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11

04 أغسطس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Eyenovia to Participate in Two Upcoming Investor Conferences

07 يوليو 2021 15:01:00 بحسب Nasdaq GlobeNewswire

Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue

15 يونيو 2021 07:00:02 بحسب Nasdaq GlobeNewswire